Cytobiologics is the sole marketing business for Promea Therapeutics’ plasma derivatives manufacturing unit (PDMU).

They are a multinational healthcare company that develops plasma-derived therapies to assist millions of people worldwide to live more productive lives in a more sustainable society by leveraging our ever-expanding knowledge of plasma, life sciences ethical leadership, and industry-leading quality and safety standards.